See more : Marsden Maritime Holdings Limited (MMH.NZ) Income Statement Analysis – Financial Results
Complete financial analysis of Ra Medical Systems, Inc. (RMED) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ra Medical Systems, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Bangkok Expressway and Metro Public Company Limited (BKKXF) Income Statement Analysis – Financial Results
- Jerónimo Martins, SGPS, S.A. (JRONF) Income Statement Analysis – Financial Results
- iCon Group Ltd (ICON.TA) Income Statement Analysis – Financial Results
- Nkarta, Inc. (NKTX) Income Statement Analysis – Financial Results
- Gilead Sciences, Inc. (GILD.SW) Income Statement Analysis – Financial Results
Ra Medical Systems, Inc. (RMED)
About Ra Medical Systems, Inc.
Ra Medical Systems, Inc., a medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular immune-mediated inflammatory diseases. It offers destruction of arteriosclerotic blockages by laser radiation ablation, a minimally invasive excimer laser and single-use catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. The company sells its products primarily through distributors in the United States. Ra Medical Systems, Inc. was incorporated in 2002 and is headquartered in Carlsbad, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 14.00K | 22.00K | 4.41M | 7.20M | 6.26M | 5.87M | 5.98M |
| Cost of Revenue | 161.00K | 1.56M | 5.48M | 8.85M | 4.21M | 4.17M | 3.14M |
| Gross Profit | -147.00K | -1.54M | -1.08M | -1.65M | 2.05M | 1.71M | 2.84M |
| Gross Profit Ratio | -1,050.00% | -6,990.91% | -24.45% | -22.93% | 32.78% | 29.05% | 47.49% |
| Research & Development | 6.39M | 12.25M | 9.01M | 4.53M | 2.78M | 4.52M | 1.72M |
| General & Administrative | 2.23M | 0.00 | 0.00 | 0.00 | 30.44M | 0.00 | 0.00 |
| Selling & Marketing | 1.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 16.25M | 15.48M | 25.97M | 51.55M | 30.44M | 14.95M | 5.32M |
| Other Expenses | 99.00K | 2.01M | 21.00K | 788.00K | 338.00K | 0.00 | 0.00 |
| Operating Expenses | 22.64M | 27.73M | 34.98M | 56.08M | 33.21M | 19.47M | 7.04M |
| Cost & Expenses | 22.80M | 29.29M | 40.46M | 64.93M | 37.42M | 23.63M | 10.17M |
| Interest Income | 0.00 | 0.00 | 129.00K | 1.04M | 352.00K | 0.00 | 0.00 |
| Interest Expense | 3.08M | 0.00 | 108.00K | 250.00K | 14.00K | 4.00K | 3.00K |
| Depreciation & Amortization | 8.77M | 1.57M | 2.37M | 1.75M | 624.00K | 218.00K | 95.00K |
| EBITDA | -18.20M | -29.27M | -36.06M | -57.73M | -31.16M | -17.54M | -4.10M |
| EBITDA Ratio | -129,971.43% | -133,027.27% | -818.59% | -801.92% | -498.00% | -298.84% | -68.66% |
| Operating Income | -26.96M | -29.27M | -36.06M | -57.73M | -31.16M | -17.76M | -4.20M |
| Operating Income Ratio | -192,578.57% | -133,027.27% | -818.59% | -801.92% | -498.00% | -302.56% | -70.25% |
| Total Other Income/Expenses | 3.00K | 2.01M | 21.00K | 788.00K | 338.00K | -4.00K | -3.00K |
| Income Before Tax | -26.86M | -27.26M | -36.04M | -56.94M | -30.82M | -17.76M | -4.20M |
| Income Before Tax Ratio | -191,871.43% | -123,895.45% | -818.12% | -790.97% | -492.60% | -302.62% | -70.30% |
| Income Tax Expense | 3.00K | 4.00K | 7.00K | 15.00K | 10.00K | 1.00K | 1.00K |
| Net Income | -26.87M | -27.26M | -36.05M | -56.96M | -30.83M | -17.77M | -4.20M |
| Net Income Ratio | -191,892.86% | -123,913.64% | -818.27% | -791.18% | -492.76% | -302.64% | -70.31% |
| EPS | -25.98 | -269.91 | -1.06K | -5.42K | -4.18K | -1.83K | -433.96 |
| EPS Diluted | -25.98 | -269.91 | -1.06K | -5.42K | -4.18K | -1.83K | -433.96 |
| Weighted Avg Shares Out | 1.03M | 101.00K | 33.98K | 10.52K | 7.38K | 9.68K | 9.68K |
| Weighted Avg Shares Out (Dil) | 1.03M | 101.00K | 33.98K | 10.52K | 7.38K | 9.68K | 9.68K |
Ra Medical Systems to Report 2020 Fourth Quarter and Full Year Financial Results on March 16, 2021
CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE: RMED) announces that it will report 2020 fourth quarter and full year financial results and provide a business update after market close on Tuesday, March 16, 2021. Ra Medical management will hold an...
Will Ra Medical Systems, Inc. (RMED) Report Negative Q4 Earnings? What You Should Know
Ra Medical Systems, Inc. (RMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ra Medical Systems to Present at the H.C. Wainwright Global Life Sciences Virtual Conference
CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, announces that management will present a company overview and hold virtual meetings with investors at...
Ra Medical Systems Reports Progress with Extending DABRA Catheter Shelf Life, Completes Quality Improvement Plan
CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, reports progress with extending the shelf life of its more robust, next generation DABRA catheter,...
Ra Medical Systems to Present at H.C. Wainwright Virtual BioConnect Conference
CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, announces that management will present at the H.C. Wainwright Virtual BioConnect Conference. The Ra Medical...
Ra Medical Systems Announces Settlement Resolving Previously Announced United States Department of Justice and State Investigations
CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE American: RMED) today announced it has entered into a settlement agreement that resolves civil False Claims Act claims asserted by the United States Department of Justice in an investigation previously disclosed by the...
Ra Medical Systems Announces Transfer of Listing to NYSE American
CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems moves to the NYSE American.
Ra Medical Systems Announces the Availability of its Webcast Event Discussing the Role of Excimer Lasers in the Treatment of Psoriasis During the Pandemic
CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE: RMED) announces the availability of its webcast event, The Inimitable Role of Excimer Lasers During the COVID-19 Pandemic, discussing the use of excimer lasers such as the Pharos excimer laser system for the...
The Law Offices of Frank R. Cruz Continues Its Investigation of Ra Medical Systems, Inc. (RMED) on Behalf of Investors
LOS ANGELES, Dec. 7, 2020 /PRNewswire/ -- The Law Offices of Frank R. Cruz continues its investigation of potential claims against the board of directors of Ra Medical Systems, Inc. ("Ra Medical" or the "Company") (NYSE: RMED) concerning whether the...
Reminder: Ra Medical Systems to Host Webcast Discussing the Role of Excimer Lasers in the Treatment of Psoriasis during the Pandemic
CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE: RMED) is hosting a webcast, The Inimitable Role of Excimer Lasers During the COVID-19 Pandemic, featuring Theodore J. Daly, MD, FAAD, FSPD, FASD, Director of Garden City Dermatology, discussing the use of excimer...
Source: https://incomestatements.info
Category: Stock Reports